Video

Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL

Author(s):

Ian Flinn, MD

In Partnership With:

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Following the positive results of the phase Ib study, this combination is being evaluated in a phase III randomized trial in Germany. Flinn predicts that this trial will be positive, and demonstrate the viability of this option for this patient population.

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Related Content
Jan A. Burger, MD, PhD
July 25th 2024

Time-Limited Acalabrutinib/Obinutuzumab Produces Durable Responses in Treatment-Naive CLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Moritz Fürstenau, MD, of the University of Cologne
July 17th 2024

Fixed-Duration Venetoclax-Based Combos Maintain Benefit in Frontline CLL

Ian Flinn, MD, PhD; Nicole Lamanna, MD; Jennifer R. Brown, MD, PhD; Constantine Tam, MD, MBBS
February 16th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL
July 3rd 2024

First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL

Vivek Subbiah, MD, of Sarah Cannon Research Institute
July 2nd 2024

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors